2019 Refresher-Radiotherapy for Lung Cancer
This 90 minute presentation that will be accredited with SA-CME by the ABR will review the state-of-the-art treatment approaches for lung cancer. The presentation will include best-practices for lung cancer: (1) role of lung cancer screening, (2) staging, (3) appropriate clinical work-up, (4) incorporating multi-modality imaging, (5) advanced radiation treatment planning (IMRT, SABR, hypofractionated), (6) using modern image-guidance and advanced delivery techniques (non-coplanar therapy, proton therapy, MR-guided radiotherapy). The course will also review the relevant evidence-based literature on the incorporation of radiotherapy for stages I-IV for Non-small-cell lung cancer (NSCLC), oligometastatic NSCLC, as well as limited and extensive stage SCLC.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, physicists, nurses, radiation therapists, and radiation dosimetrists.
- Explore the role of lung cancer screening, best-practices using low-dose CT for lung cancer screening, who are the optimal candidates to offer lung cancer screening, and the best treatment options for screen-detected early stage lung cancer
- Identify who are inoperable early stage NSCLC lung cancer patients, and use best-practices to deliver the highest quality SABR for these patients
- Match optimal chemoradiotherapy to patients with unresectable stage III NSCLC in conjunction with consolidative durvalumab.
- Identify optimal candidates with oligometastatic or oligoprogressive NSCLC that will most likely derive a clinical benefit with aggressive local consolidative therapies (e.g. surgery or SABR).
Percy Lee, MD is employed by the University of California, receives compensation/remuneration/funding from AstraZeneca, Inc., Varian Inc., Viewray and holds a leadership position at AAPM HYTEC Thoracic TCP Sub-committee.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.
- 1.50 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Live activity for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.50 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.